148 related articles for article (PubMed ID: 11531277)
21. Promoter hypermethylation profile of kidney cancer.
Dulaimi E; Ibanez de Caceres I; Uzzo RG; Al-Saleem T; Greenberg RE; Polascik TJ; Babb JS; Grizzle WE; Cairns P
Clin Cancer Res; 2004 Jun; 10(12 Pt 1):3972-9. PubMed ID: 15217927
[TBL] [Abstract][Full Text] [Related]
22. Microvessel density and CpG island methylation of the THBS2 gene in malignant ovarian tumors.
Czekierdowski A; Czekierdowska S; Danilos J; Czuba B; Sodowski K; Sodowska H; Szymanski M; Kotarski J
J Physiol Pharmacol; 2008 Sep; 59 Suppl 4():53-65. PubMed ID: 18955754
[TBL] [Abstract][Full Text] [Related]
23. Differential distribution of DNA methylation within the RASSF1A CpG island in breast cancer.
Yan PS; Shi H; Rahmatpanah F; Hsiau TH; Hsiau AH; Leu YW; Liu JC; Huang TH
Cancer Res; 2003 Oct; 63(19):6178-86. PubMed ID: 14559801
[TBL] [Abstract][Full Text] [Related]
24. Genome-wide profiling of CpG methylation identifies novel targets of aberrant hypermethylation in myeloid leukemia.
Gebhard C; Schwarzfischer L; Pham TH; Schilling E; Klug M; Andreesen R; Rehli M
Cancer Res; 2006 Jun; 66(12):6118-28. PubMed ID: 16778185
[TBL] [Abstract][Full Text] [Related]
25. Hypermethylation of let-7a-3 in epithelial ovarian cancer is associated with low insulin-like growth factor-II expression and favorable prognosis.
Lu L; Katsaros D; de la Longrais IA; Sochirca O; Yu H
Cancer Res; 2007 Nov; 67(21):10117-22. PubMed ID: 17974952
[TBL] [Abstract][Full Text] [Related]
26. Hypermethylation in histologically distinct classes of breast cancer.
Bae YK; Brown A; Garrett E; Bornman D; Fackler MJ; Sukumar S; Herman JG; Gabrielson E
Clin Cancer Res; 2004 Sep; 10(18 Pt 1):5998-6005. PubMed ID: 15447983
[TBL] [Abstract][Full Text] [Related]
27. High-resolution methylation analysis of the BRCA1 promoter in ovarian tumors.
Wilcox CB; Baysal BE; Gallion HH; Strange MA; DeLoia JA
Cancer Genet Cytogenet; 2005 Jun; 159(2):114-22. PubMed ID: 15899382
[TBL] [Abstract][Full Text] [Related]
28. Identification of PRTFDC1 silencing and aberrant promoter methylation of GPR150, ITGA8 and HOXD11 in ovarian cancers.
Cai LY; Abe M; Izumi S; Imura M; Yasugi T; Ushijima T
Life Sci; 2007 Mar; 80(16):1458-65. PubMed ID: 17303177
[TBL] [Abstract][Full Text] [Related]
29. Spreading of methylation within RUNX3 CpG island in gastric cancer.
Homma N; Tamura G; Honda T; Matsumoto Y; Nishizuka S; Kawata S; Motoyama T
Cancer Sci; 2006 Jan; 97(1):51-6. PubMed ID: 16367921
[TBL] [Abstract][Full Text] [Related]
30. WT1 and WT1-AS genes are inactivated by promoter methylation in ovarian clear cell adenocarcinoma.
Kaneuchi M; Sasaki M; Tanaka Y; Shiina H; Yamada H; Yamamoto R; Sakuragi N; Enokida H; Verma M; Dahiya R
Cancer; 2005 Nov; 104(9):1924-30. PubMed ID: 16134181
[TBL] [Abstract][Full Text] [Related]
31. Prognostic implications of and relationship between CpG island hypermethylation and repetitive DNA hypomethylation in hepatocellular carcinoma.
Lee HS; Kim BH; Cho NY; Yoo EJ; Choi M; Shin SH; Jang JJ; Suh KS; Kim YS; Kang GH
Clin Cancer Res; 2009 Feb; 15(3):812-20. PubMed ID: 19188151
[TBL] [Abstract][Full Text] [Related]
32. Global methylation profiling in serous ovarian cancer is indicative for distinct aberrant DNA methylation signatures associated with tumor aggressiveness and disease progression.
Keita M; Wang ZQ; Pelletier JF; Bachvarova M; Plante M; Gregoire J; Renaud MC; Mes-Masson AM; Paquet ÉR; Bachvarov D
Gynecol Oncol; 2013 Feb; 128(2):356-63. PubMed ID: 23219462
[TBL] [Abstract][Full Text] [Related]
33. Detection of hypermethylated genes in tumor and plasma of cervical cancer patients.
Yang HJ; Liu VW; Wang Y; Chan KY; Tsang PC; Khoo US; Cheung AN; Ngan HY
Gynecol Oncol; 2004 May; 93(2):435-40. PubMed ID: 15099958
[TBL] [Abstract][Full Text] [Related]
34. DNA methylation changes in ovarian cancer: implications for early diagnosis, prognosis and treatment.
Barton CA; Hacker NF; Clark SJ; O'Brien PM
Gynecol Oncol; 2008 Apr; 109(1):129-39. PubMed ID: 18234305
[TBL] [Abstract][Full Text] [Related]
35. Diagnostic and prognostic information in prostate cancer with the help of a small set of hypermethylated gene loci.
Bastian PJ; Ellinger J; Wellmann A; Wernert N; Heukamp LC; Müller SC; von Ruecker A
Clin Cancer Res; 2005 Jun; 11(11):4097-106. PubMed ID: 15930345
[TBL] [Abstract][Full Text] [Related]
36. Microarray-based survey of CpG islands identifies concurrent hyper- and hypomethylation patterns in tissues derived from patients with breast cancer.
Piotrowski A; Benetkiewicz M; Menzel U; Díaz de Ståhl T; Mantripragada K; Grigelionis G; Buckley PG; Jankowski M; Hoffman J; Bała D; Srutek E; Laskowski R; Zegarski W; Dumanski JP
Genes Chromosomes Cancer; 2006 Jul; 45(7):656-67. PubMed ID: 16575877
[TBL] [Abstract][Full Text] [Related]
37. Methylation profiling of CpG islands in human breast cancer cells.
Huang TH; Perry MR; Laux DE
Hum Mol Genet; 1999 Mar; 8(3):459-70. PubMed ID: 9949205
[TBL] [Abstract][Full Text] [Related]
38. Integrative genome-wide expression and promoter DNA methylation profiling identifies a potential novel panel of ovarian cancer epigenetic biomarkers.
Gloss BS; Patterson KI; Barton CA; Gonzalez M; Scurry JP; Hacker NF; Sutherland RL; O'Brien PM; Clark SJ
Cancer Lett; 2012 May; 318(1):76-85. PubMed ID: 22155104
[TBL] [Abstract][Full Text] [Related]
39. Progression-free survival in ovarian cancer is reflected in epigenetic DNA methylation profiles.
Bauerschlag DO; Ammerpohl O; Bräutigam K; Schem C; Lin Q; Weigel MT; Hilpert F; Arnold N; Maass N; Meinhold-Heerlein I; Wagner W
Oncology; 2011; 80(1-2):12-20. PubMed ID: 21577013
[TBL] [Abstract][Full Text] [Related]
40. Methylation status of oestrogen receptor-alpha gene promoter sequences in human ovarian epithelial cell lines.
O'Doherty AM; Church SW; Russell SE; Nelson J; Hickey I
Br J Cancer; 2002 Jan; 86(2):282-4. PubMed ID: 11870520
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
